concluded that treatment with standard melphalan and prednisolone (M/P) was ineffective, with a median survival of 2.0 months, but more intensive chemotherapy induced Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder characterized by a malignant proliferresponses in approximately one half of patients, with a median survival of 20.0 months. [6] [7] [8] [9] [10] [11] Patients with secondary ation of plasma cells in blood and bone marrow. Treatment of primary PCL has been mostly disappointing.
Three patients with plasma cell leukemia (PCL) were included. Median age was 58 years, and all women. Two Plasma cell leukemia (PCL) is a rare lymphoproliferative patients had Bence-Jones (BJ) paraprotein ( and light disorder characterized by a malignant proliferation of chain) and one patient had IgG-. All patients had more plasma cells in blood and bone marrow.
than 50% plasma cells in the bone marrow which were Two forms of PCL can be distinguished. The primary positive for CD19, CD38 and BB4 as tested by FACS form occurs in individuals without preceding multiple analysis (Becton Dickinson, CA, USA; CD19, CD38; myeloma (MM) and normally with a rapid clinical course Becton Dickinson Immunocytometry Systems, San Jose, and a short survival. The second form of PCL typically CA, USA; BB4; Immuno Quality Products, Groningen, The arises as a late manifestation in individuals with MM in 1-Netherlands respectively). Peripheral blood cells contained 2% of cases. Additional clinical characteristics of this group more than 60% plasma cells in all cases which were include a high frequency of extramedullary disease, severe CD38/BB4 positive. Two cases had lytic bone lesions. anaemia and thrombocytopenia. [1] [2] [3] [4] According to the Durie-Salmon staging system, two Patients treated for PCL with standard alkylating agents patients had stage III-A and one patient stage III-B. The and steroids have a short survival, ranging from 2 to median increase in ␤ 2 -microglobulin found at presentation 6 months.
1-4 Vincristine, doxorubicine and dexamethasone was 11.0 mg/l (range 7.0-17.6 mg/l, normal 1.0-3.0 mg/l 14 months the oligoclonality is still present. It was noticed that all patients developed oligoclonality post-transplantation. In one patient the oligoclonality had a transient character and disappeared 16 months post-transDiscussion plantation, while the second patient developed progressive IgG-paraprotein with different oligoclonal bands at The present study represents three patients with primary plasma cell leukemia (PCL) treated with high-dose melrelapse. The data suggest that the cause of the oligoclonality might vary between different patients, an imbalance in phalan supported by PSC after induction therapy with VAD, high-dose cyclophosphamide and EDAP courses. CR the B cell development post-transplantation or a dedifferentiation of the malignant B cell clone. was attained in all cases. The decline in tumor load was most pronounced after VAD, indicating a very effective In summary, these data suggest that dose-intensification might prolong the survival of patients with PCL. chemotherapy regimen for remission induction. Consolidation was further obtained with high-dose cyclophosphamide, EDAP and HDM with peripheral stem cell support. Long-term follow-up demonstrated two survivors, whereas
